Check-Cap (NASDAQ:CHEK) versus SiBone (NASDAQ:SIBN) Head-To-Head Contrast

SiBone (NASDAQ:SIBN) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Volatility and Risk

SiBone has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Earnings & Valuation

This table compares SiBone and Check-Cap”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$167.18 million	4.00	-$30.91 million	($0.56)	-27.66
Check-Cap	N/A	N/A	-$25.15 million	($2.77)	-0.58

Check-Cap has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SiBone and Check-Cap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-12.83%	-14.20%	-10.38%
Check-Cap	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for SiBone and Check-Cap, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	3	0	2.50
Check-Cap	1	0	0	0	1.00

SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 48.48%. Given SiBone’s stronger consensus rating and higher possible upside, equities analysts clearly believe SiBone is more favorable than Check-Cap.

Insider & Institutional Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

SiBone beats Check-Cap on 8 of the 13 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.